View Older Stories View More Recent Stories
-
Trump discusses price gouging of 'fat drugs' in the U.S.
-
Trump to pitch sweeping Medicare drug price plan - Politico
-
Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK850 at BofA Securities
-
Novo Nordisk (NVO) Reports Q1 EPS of DKK6.53
-
Novo Nordisk earnings preview: Q1 miss, guidance cut in focus as obesity drug demand cools
-
Novo Nordisk (NVO) call put ratio 1.3 calls to 1 put into quarter results
-
Novo Nordisk (NVO) May 9 weekly straddle priced into quarter results
-
Novo Nordisk shares jump as FDA accepts oral Wegovy application
-
FDA accepts filing application for Novo Nordisk's (NVO) Wegovy oral form
-
Hims & Hers shares surge over 40% on Wegovy pact with Novo Nordisk
-
Hims & Hers Health, Inc. (HIMS) Short Sellers Pressured as Shares Spike Following Novo Nordisk (NVO) Pact
-
Hims & Hers Health, Inc. (HIMS) and Novo Nordisk Team Up to Expand Affordable Access to Care
-
BMO Capital Downgrades Novo Nordisk (NVO) to Market Perform
-
BNP Paribas Exane Starts Novo Nordisk (NOVOB:DC) (NVO) at Underperform
-
Pharma stocks slide after Trump signals tariffs on sector
-
Novo Nordisk (NVO) to invest 6.4B Reais to increase factory capacity in Brazil - CEO
-
Trump Admin Drops Biden Medicare Obesity Drug Coverage Proposal - Bloomberg
-
Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851
-
Novo Nordisk (NVO) call put ratio 1 call to 2.2 puts amid wide price movement
-
2 reasons why Novo Nordisk shares may underperform in near term: analyst
-
Weighing in on obesity: Catalyst-rich 2025 ahead in a growing competitive landscape
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
FINAL REMINDER NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Novo Nordisk A/S Investors to Participate in the Class Action Lawsuit!
-
NVO DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - NVO
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO)
-
FINAL REMINDER NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Novo Nordisk A/S Investors to Participate in the Class Action Lawsuit!
-
NVO DEADLINE TOMORROW: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - NVO
-
Novo Nordisk (NVO) expands Wegovy $499-per-month offering to additional cash-paying patients via the Wegovy savings offer
-
NVO DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - NVO
-
NVO DEADLINE ALERT: Novo Nordisk (NVO) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 25th Deadline in Securities Class Action
-
NVO DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
NVO DEADLINE ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
NVO DEADLINE ALERT: Novo Nordisk (NVO) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 25th Deadline in Securities Class Action
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
NVO DEADLINE; ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
Kepler Cheuvreux Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Buy
-
Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
-
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
Novo Nordisk A/S (NVO): CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
-
ROSEN, A LEADING AND RANKED FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
